Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
6/2018 not set
Rosetta Genomics
Rosetta Genomics Overview
Rosetta Genomics develops and commercializes a range of microRNA-based and other molecular diagnostics. The companys integrative research platform, combining bioinformatics and laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs.
Rosetta Genomics is advancing and developing multiple diagnostic programs for cancer and various other indications to enable accurate diagnosis and prognosis and to improve patient care management worldwide.
The RosettaGX platform of tests uses blended technology platforms (e.g. microRNA, FISH, and next-generation sequencing) along with proprietary scientific approaches for each tumor type in its offering. It chooses the most clinically informative and relevant testing based on an ongoing and thorough review of scientific literature and an internal medical review process.
Rosetta Genomics Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Jun 4, 2018
www.genomeweb.com
Rosetta Genomics Files for Chapter 7 Bankruptcy
#Acquisition #Investment #Layoffs
Dec 17, 2017
www.globes.co.il
Rosetta Genomics sold for $10m
#Acquisition #Investment
Sep 8, 2017
www.genomeweb.com
Rosetta Genomics Inks Deal to Sell PersonalizeDx for $2.9M